Project Grant R21LM015664
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $200K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Medical Branch at Galveston $294,150 on August 1, 2026, for research on defective pro-viruses and viral proteins in neuroHIV and HIV cure strategies under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research employs correlative microscopy (live-cell, confocal, and electron microscopy), mass spectrometry imaging, and spatial proteomic and mRNA analysis to detect, quantify, and...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Health Science Center at Houston $234,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and analyze symptom clusters in people living with HIV who have co-morbid diabetes and hypertension. The research employs topic modeling, specifically latent Dirichlet allocation, to discover latent symptom clusters using data from the Center for AIDS Research Network of...
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute on Drug Abuse, a component of the National Institutes of Health, awarded the University of Pennsylvania $500,000 on May 18, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test multimodal artificial intelligence and machine learning models that integrate structured and unstructured electronic health record data, claims, pharmacy records, genomics data, and imaging data to enhance personalized clinical decision support and address unmet...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $2,461,651 to the University of Texas Health Science Center at Houston under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, for a project extending through July 31, 2029. The project investigates estrogen's impact on immunoglobulin G (IgG) glycomic modulation of immunity and inflammation in people with human immunodeficiency virus (HIV) on antiretroviral...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Health Science Center at San Antonio $855,899 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to implement and test PL4Y (PositiveLinks for Youth), a mobile health intervention designed to improve care engagement and virologic suppression among young adults with HIV ages 18–29 in Texas. PL4Y is a multimodal intervention delivering daily adherence and mood...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Maryland Baltimore County $246,070 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the phosphorylation and dephosphorylation of antiretroviral drugs tenofovir and emtricitabine in colonic tissue using mass spectrometry imaging-based enzyme histochemistry. The research addresses variability in clinical...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on October 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct natural language processing analysis of social media discussions about pre-exposure prophylaxis (PrEP). The research uses NLP to extract user-generated posts about PrEP from ten years of Google and Reddit data, identifying public inquiries and concerns about initiating or continuing the medication. The...
- The National Institute of Mental Health awarded Duke University $1.221 million under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop an AI-driven multimodal model for HIV pre-exposure prophylaxis (PrEP) candidacy assessment in women in the South, where 52% of new HIV infections occur nationally but PrEP use remains lower than in other regions and women account for a disproportionate share of new infections. The award funds development of a clinically...